# A Study of RO5429083 in Patients With Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid Tumors

> **NCT01358903** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 65 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** RO5429083
- **DRUG:** RO5429083

## Key facts

- **NCT ID:** NCT01358903
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2014-03
- **Final completion:** 2014-03
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01358903

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01358903, "A Study of RO5429083 in Patients With Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01358903. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*